BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Rosiglitazone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00297063

AVD104742

Details and patient eligibility

About

This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.

Enrollment: 350 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes mellitus.
• Managed by diet therapy.
• Must have adequate blood, liver and kidney function.

Exclusion criteria

• Serious cardiovascular disease or serious hepatic disease.